

EXTRAORDINARY GENERAL MEETING

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)

(Company Registration No.91120000103100784F)

(Incorporated in the People's Republic of China)

(the “**Company**”)

NOTICE OF EXTRAORDINARY GENERAL MEETING

IMPORTANT NOTE FOR S-SHAREHOLDERS:

This Notice of Extraordinary General Meeting has been given in compliance with Article 69 of the Articles of Association of the Company and the listing rules of the Shanghai Stock Exchange which requires the Company to issue a written notice 45 days in advance of a shareholders' meeting.

The Company will issue an updated Notice of Extraordinary General Meeting 14 days before the Extraordinary General Meeting in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, to provide the S-Shareholders with the details in relation to the arrangements for participation at the Extraordinary General Meeting by S-Shareholders in Singapore. S-Shareholders should check the SGXNET for the latest updates on the status of the Extraordinary General Meeting.

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (“**EGM**” or “**Extraordinary General Meeting**”) of the Company will be held at the meeting room of Da Ren Tan Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the People's Republic of China 300193 on 30 December 2022 at 2:00 p.m.. Concurrently, a video conferencing for holders of “S” shares (“**S-Shareholders**”) will be held in Singapore at an address to be announced in due course (*see Note 2*).

To consider and, if thought fit, approve the following resolutions, with or without modifications:

Resolution 1: To consider and approve the proposed re-appointment of ShineWing Certified Public Accountants LLP as the People's Republic of China (the “**PRC**”) auditors of the Company for the financial year ending 31 December 2022 (“**FY2022**”), re-appointment of RSM Chio Lim LLP as international auditors of the Company for FY2022, and to propose for the shareholders of the Company at the Extraordinary General Meeting to authorise the Board to determine their respective remuneration;

Resolution 2: To consider and approve the proposed adjustments to the implementation plan for the provision of an entrusted loan (委托贷款) of RMB1,200 million by the Company to its wholly-owned subsidiary, Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司);

Resolution 3: To consider and approve the proposed appointment of Ms. Mao Weiwen (毛蔚雯) as a Non-Executive Director of the Company with effect from the date of the Extraordinary General Meeting;

Resolution 4: To consider and approve the proposed appointment of Ms. Wang Lei (王磊) as an Executive Director of the Company with effect from the date of the Extraordinary General Meeting; and

Resolution 5: To consider and approve the proposed appointment of Mr. Zhu Haifeng (朱海峰) as an

Independent Director of the Company with effect from the date of the Extraordinary General Meeting.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
14 November 2022

Notes:

1. Resolution 1 has been approved by the Board at the Board meeting of the Company held on 12 August 2022, and Resolutions 2 to 5 have been approved by the Board at the Board meeting of the Company held on 8 November 2022.
2. The EGM will be held by a video conferencing for S-Shareholders in Singapore as per the Company's past practice pre-COVID. **The venue for S-Shareholders to attend the EGM in Singapore via video-conference is being arranged and will be announced in due course.** As disclosed above, the Company will issue an updated Notice of Extraordinary General Meeting 14 days before the Extraordinary General Meeting in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, to provide the S-Shareholders with the details in relation to the arrangements for participation at the Extraordinary General Meeting by S-Shareholders in Singapore. S-Shareholders should check the SGXNET for the latest updates on the status of the Extraordinary General Meeting.
3. A holder of shares entitled to attend and vote at the EGM (other than S-Shareholders) is entitled to appoint one or more persons (who need not also be shareholders) to act as their proxies to attend and vote on their behalf.

If the appointor is a corporation, the proxy must be executed under seal or the hand of its duly authorised officer or attorney.

4. Pursuant to the Articles of Association of the Company, a holder of tradable domestic shares with limiting conditions for sale shall notify the Company in writing not less than 20 days prior to the EGM of his or her intention to attend the EGM. A holder of "S" share shall be registered in the shareholder name list or in the Depository Register 48 hours before the appointed time for holding the EGM.

A holder of tradable domestic shares with limiting conditions for sale who is planning to attend the EGM must give a written notice to the Company no later than 6 December 2022.

5. The EGM in Tianjin, PRC is expected to last for half a day and all accommodation and other expenses incurred by a shareholder or his/her proxy in connection with his/her attendance at the EGM shall be borne by that shareholder.
6. As the COVID-19 situation continues to evolve, the Company may be required to change its arrangements in Singapore at short notice. S-Shareholders should check SGXNET and/or our corporate website at www.jydr.com.cn for the latest updates on the status of the EGM.

7. The Company thanks all members for their understanding and cooperation to hold the EGM in line with appropriate safe distancing measures amidst the COVID-19 pandemic.
8. **Personal data privacy:** By submitting a proxy form appointing a proxy(ies) and/or representative(s) to attend, speak and vote at the Extraordinary General Meeting and/or any adjournment thereof, a shareholder of the Company (1) consents to the collection, use and disclosure of the shareholder's personal data by the Company (or its agents or service providers) for the purpose of (i) the processing and administration by the Company (or its agents or service providers) of proxies and representatives appointed for the Extraordinary General Meeting (including any adjournment thereof) and (ii) the preparation and compilation of the attendance lists, minutes and other documents relating to the Extraordinary General Meeting (including any adjournment thereof), and in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/or guidelines (collectively, the "**Purposes**"), (2) warrants that where the shareholder discloses the personal data of the shareholder's proxy(ies) and/or representative(s) to the Company (or its agents or service providers), the shareholder has obtained the prior consent of such proxy(ies) and/or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/or representative(s) for the Purposes, and (3) agrees that the shareholder will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the shareholder's breach of warranty.